<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02173977</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-14-1078-RO-CTIL</org_study_id>
    <nct_id>NCT02173977</nct_id>
  </id_info>
  <brief_title>Ultrashort GnRH Agonist/Antagonist Versus GnRH Antagonist IVF</brief_title>
  <official_title>Ultrashort Flare GnRH Agonist Combined With Flexible Multidose GnRH Antagonist Versus Flexible Multidose GnRH Antagonist for Good-prognosis IVF Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the appropriate controlled ovarian hyperstimulation
      (COH) protocol in good prognosis patients undergoing IVF treatment. The stimulation
      characteristics of cycles which include ultrashort flare GnRH agonist combined with flexible
      multidose GnRH antagonist will be compared to the flexible multidose GnRH antagonist
      protocol.

      The investigators hypothesized that combining the stimulatory effect of GnRH agonists and
      immediate suppression of the GnRH antagonist in a unique protocol may be a valuable new COH
      strategy for IVF patients, resulting in improved ART outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ultrashort flare GnRH agonist combined with flexible multidose GnRH antagonist protocol
      during COH cycle resulted in a significantly higher clinical pregnancy rate in patients with
      poor embryo quality, with repeated IVF failures and in poor responders. This protocol
      combines the effect of the microdose flare on endogenous follicle stimulating hormone (FSH)
      release with the benefit of an immediate luteinizing hormone suppression of the GnRH
      antagonist.

      The basic hypothesis of this approach can also benefit IVF patients with good prognosis
      without compromising the ability to use gonadotrophin-releasing hormone (GnRH) agonist to
      effectively trigger ovulation, while completely eliminating any threat of clinically
      significant ovarian hyperstimulation syndrome (OHSS).

      The purpose of the study is to compare cycles consisting of ultrashort flare GnRH agonist
      combined with flexible multidose GnRH antagonist with those using the flexible multidose GnRH
      antagonist protocol

      1. To compare the IVF outcome variables and ongoing pregnancy rates.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing pregnancy rates</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total gonadotropin use</measure>
    <time_frame>2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical pregnancy</measure>
    <time_frame>2 Years</time_frame>
    <description>Positive pregnancy test without documentation of intrauterine or extrauterine pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy</measure>
    <time_frame>2 Years</time_frame>
    <description>Positive pregnancy test with documentation of intrauterine or extrauterine pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple pregnancy rate</measure>
    <time_frame>2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriage rate</measure>
    <time_frame>2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilization rate</measure>
    <time_frame>2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of oocytes</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OHSS rates</measure>
    <time_frame>2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryo quality</measure>
    <time_frame>2 Years</time_frame>
    <description>Grading of a day 3 embryo based on the number of cells that make up the embryo, the amount of fragmentation, and the symmetry of each of the embryo's cells (blastomeres).
E.g. good quality embryos: embryos that reach the eight-cell stage with less than 20% fragmentation on day 3</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Positive Pregnancy Test</measure>
    <time_frame>2 Years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>ARM A- Agonist/Antagonist protocol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The Ultrashort GnRH Agonist/antagonist method entails pre-treatment with oral contraceptive pills before the combination of GnRH ultrashort agonist and antagonist protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM B- Antagonist protocol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The standard IVF method entails Flexible Multidose GnRH Antagonist protocol during COH</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ARM A- Agonist/Antagonist protocol</intervention_name>
    <description>In vitro fertilization (IVF/ICSI)</description>
    <arm_group_label>ARM A- Agonist/Antagonist protocol</arm_group_label>
    <arm_group_label>ARM B- Antagonist protocol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ARM B- Antagonist protocol</intervention_name>
    <description>In vitro fertilization (IVF/ICSI)</description>
    <arm_group_label>ARM A- Agonist/Antagonist protocol</arm_group_label>
    <arm_group_label>ARM B- Antagonist protocol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Up to three previous IVF attempts

        Exclusion Criteria:

          -  Patients with poor or no response in previous COH for IVF cycles

          -  Abnormal ovarian reserve test i.e. anti-mullerian hormone (AMH), Antral follicle test

          -  Risk factor for Diminished Ovarian Reserve
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raoul Orvieto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Infertility &amp; IVF Unit, Dept. Obstetrics &amp; Gynecology - Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sheba Medical Center- IVF unit</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Orvieto R, Nahum R, Rabinson J, Gemer O, Anteby EY, Meltcer S. Ultrashort flare GnRH agonist combined with flexible multidose GnRH antagonist for patients with repeated IVF failures and poor embryo quality. Fertil Steril. 2009 Apr;91(4 Suppl):1398-400. doi: 10.1016/j.fertnstert.2008.04.064. Epub 2008 Aug 3.</citation>
    <PMID>18675974</PMID>
  </reference>
  <reference>
    <citation>Orvieto R. The ultrashort flare GnRH-agonist/GnRH-antagonist protocol enables cycle programming and may overcome the &quot;detrimental effect&quot; of the oral contraceptive. Fertil Steril. 2012 Sep;98(3):e17-8; author reply e19. doi: 10.1016/j.fertnstert.2012.06.053. Epub 2012 Jul 26.</citation>
    <PMID>22840381</PMID>
  </reference>
  <reference>
    <citation>Orvieto R, Nahum R, Zohav E, Liberty G, Anteby EY, Meltcer S. GnRH-agonist ovulation trigger in patients undergoing controlled ovarian hyperstimulation for IVF with ultrashort flare GnRH-agonist combined with multidose GnRH-antagonist protocol. Gynecol Endocrinol. 2013 Jan;29(1):51-3. doi: 10.3109/09513590.2012.705376. Epub 2012 Aug 3.</citation>
    <PMID>22857268</PMID>
  </reference>
  <reference>
    <citation>Orvieto R, Meltcer S, Liberty G, Rabinson J, Anteby EY, Nahum R. A combined approach to patients with repeated IVF failures. Fertil Steril. 2010 Nov;94(6):2462-4. doi: 10.1016/j.fertnstert.2010.03.057. Epub 2010 May 7.</citation>
    <PMID>20451192</PMID>
  </reference>
  <reference>
    <citation>Orvieto R, Kruchkovich J, Rabinson J, Zohav E, Anteby EY, Meltcer S. Ultrashort gonadotropin-releasing hormone agonist combined with flexible multidose gonadotropin-releasing hormone antagonist for poor responders in in vitro fertilization/embryo transfer programs. Fertil Steril. 2008 Jul;90(1):228-30. Epub 2007 Aug 6.</citation>
    <PMID>17681292</PMID>
  </reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2014</study_first_submitted>
  <study_first_submitted_qc>June 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <last_update_submitted>June 23, 2014</last_update_submitted>
  <last_update_submitted_qc>June 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GnRH Agonist</keyword>
  <keyword>GnRH Antagonist</keyword>
  <keyword>OHSS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deslorelin</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

